CBT
GCVRZ

Central Bank & Trust’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Central Bank & Trust’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-3,225
Closed -$6.59K – 332
2013
Q2 		$6.59K Buy
+3,225
New +$5.67K ﹤0.01% 274

Other funds holding GCVRZ

ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
DI
Dalton Investments Las Vegas, Nevada $103M AUM 3.77% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
AAA
Alpine Associates Advisors Englewood Cliffs, New Jersey $158M AUM 48.85% 1-Year Est. Return
NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Central Bank & Trust's GCVRZ Position: Q3 2013 in Review

Central Bank & Trust sold out of Sanofi Contingent Value Rights (GCVRZ) in Q3 2013, closing a stake of 3,225 shares — an estimated $6.59K sold.

Central Bank & Trust first reported a position in GCVRZ in Q2 2013 and held it in 1 quarter. The position peaked at $6.59K in Q2 2013. 136 funds tracked by Wall St. Rank hold GCVRZ as of Q3 2013.

  • Central Bank & Trust reported no remaining Sanofi Contingent Value Rights position as of Q3 2013 after selling out during the quarter.
  • Central Bank & Trust sold 3,225 Sanofi Contingent Value Rights shares in Q3 2013, an estimated $6.59K.
  • Central Bank & Trust first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 1 quarter.
  • Central Bank & Trust's Sanofi Contingent Value Rights position peaked at $6.59K in Q2 2013.
  • 136 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q3 2013.

Based on Central Bank & Trust's 13F filing for Q3 2013, filed 30 Oct 2013.